Please assess the completion status of the following clinical trial:

Trial Title: Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Relapsed multiple myeloma~2. Refractory multiple myeloma defined as meeting 1 or more of the following:~   * Nonresponsive to most recent therapy (stable disease only or PD while on treatment), or~  * Disease progression within 60 days of discontinuation from most recent therapy~3. At least 2 but no more than 3 prior therapies for multiple myeloma~4. Prior exposure to an immunomodulatory agent (IMiD)~5. Prior exposure to a proteasome inhibitor (PI)~6. Documented response of at least partial response (PR) to 1 line of prior therapy~7. Measurable disease with at least 1 of the following assessed within the 21 days prior to randomization:~   * Serum M-protein ≥ 0.5 g/dL~  * Urine M-protein ≥ 200 mg/24 hours~  * In subjects without detectable serum or urine M-protein, serum free light chain (SFLC) \> 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio~8. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1~9. Left ventricular ejection fraction (LVEF) ≥ 40% within the 21 days prior to randomization~10. Adequate organ and bone marrow function within the 21 days prior to randomization defined by:~    * Bilirubin \< 1.5 times the upper limit of normal (ULN)~   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 times the ULN~   * Absolute neutrophil count (ANC) ≥ 1000/mm³ (screening ANC should be independent of growth factor support for ≥ 1 week)~   * Hemoglobin ≥ 8.0 g/dL (Use of erythropoietic stimulating factors and red blood cell \[RBC\] transfusion per institutional guidelines is allowed, however the most recent RBC transfusion may not have been done within 7 days prior to obtaining screening hemoglobin.)~   * Platelet count ≥ 50,000/mm³ (≥ 30,000/mm³ if myeloma involvement in the bone marrow is \> 50%. Subjects should not have received platelet transfusions for at least 1 week prior to obtaining the screening platelet count.)~   * Calculated or measured creatinine clearance (CrCl) of ≥ 30 mL/min~Key Exclusion Criteria:~1. Waldenström macroglobulinemia~2. Multiple myeloma of Immunoglobin M (IgM) subtype~3. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)~4. Plasma cell leukemia (\> 2.0 × 10⁹/L circulating plasma cells by standard differential)~5. Myelodysplastic syndrome~6. Second malignancy within the past 5 years except:~   * Adequately treated basal cell or squamous cell skin cancer~  * Carcinoma in situ of the cervix~  * Prostate cancer \< Gleason score 6 with stable prostate-specific antigen (PSA) over 12 months~  * Ductal breast carcinoma in situ with full surgical resection (i.e., negative margins)~  * Treated medullary or papillary thyroid cancer~  * Similar condition with an expectation of \> 95% five-year disease-free survival~7. History of or current amyloidosis~8. Cytotoxic chemotherapy within the 28 days prior to randomization~9. Immunotherapy within the 21 days prior to randomization~10. Glucocorticoid therapy within the 14 days prior to randomization that exceeds a cumulative dose of 160 mg of dexamethasone or 1000 mg prednisone~11. Radiation therapy:~    * Focal therapy within the 7 days prior to randomization~   * Extended field therapy within the 21 days prior to randomization~12. Prior treatment with either carfilzomib or oprozomib~13. Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)~14. Contraindication to dexamethasone or any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs, or intolerance to hydration due to pre-existing pulmonary or cardiac impairment~15. Active congestive heart failure (New York Heart Association \[NYHA\] Class III or IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, acute diffuse infiltrative pulmonary disease, pericardial disease, or myocardial infarction within 6 months prior to enrollment~16. Active infection within the 14 days prior to randomization requiring systemic antibiotics~17. Pleural effusions requiring thoracentesis within the 14 days prior to randomization~18. Ascites requiring paracentesis within the 14 days prior to randomization~19. Ongoing graft-versus-host disease~20. Uncontrolled hypertension or uncontrolled diabetes despite medication~21. Significant neuropathy (≥ Grade 3) within the 14 days prior to randomization~22. Known cirrhosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone (Type: EXPERIMENTAL): Participants received carfilzomib administered by intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle (20 mg/m² on day 1 of cycle 1 and 70 mg/m² thereafter).~Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15.
- Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone (Type: EXPERIMENTAL): Participants received carfilzomib administered by IV infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter).~Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete